Skip to Content

Arixtra 10 mg / dose (fondaparinux) Disease Interactions

There are 6 disease interactions with Arixtra 10 mg / dose (fondaparinux):

Major

Factor Xa inhibitors (applies to Arixtra 10 mg/dose) bleeding

Major Potential Hazard, Moderate plausibility.

The use of factor Xa inhibitors is contraindicated in patients with active pathological bleeding. Its use increases the risk of bleeding and can cause serious or fatal bleeding. Caution is recommended when prescribing these agents to patients at increased risk of bleeding. When using these agents, the risk of thrombotic events should be weighed against the risk of bleeding.

Major

Factor Xa inhibitors (applies to Arixtra 10 mg/dose) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

In general, the manufacturer recommends avoiding the use of factor Xa inhibitors in patients with moderate and severe hepatic impairment or with any hepatic disease associated with coagulopathy as drug exposure and bleeding risk may be increased.

Major

Factor Xa inhibitors (applies to Arixtra 10 mg/dose) renal disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Some factor Xa inhibitors such as rivaroxaban and fondaparinux should be avoided in patients with CrCl <30 mL/min. Observe closely and promptly evaluate any signs or symptoms of blood loss in patients with CrCl 30 to 50 mL/min. Treatment should be discontinued in patients who develop acute renal failure while on treatment with these drugs.

Major

Factor Xa inhibitors (applies to Arixtra 10 mg/dose) valvular heart disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Prosthetic Heart Valves

The use of factor Xa inhibitors is not recommended in patients with prosthetic heart valves as no studies have been conducted for safety and efficacy.

Major

Fondaparinux (applies to Arixtra 10 mg/dose) bacterial endocarditis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Endocarditis

The manufacturers state that bacterial endocarditis is a contraindication for the use of fondaparinux injection.

Moderate

Fondaparinux (applies to Arixtra 10 mg/dose) thrombocytopenia

Moderate Potential Hazard, Moderate plausibility.

Thrombocytopenia can occur with the administration of fondaparinux. Caution should be used when administered to patients with preexisting thrombocytopenia. Thrombocytopenia of any degree should be monitored closely and treatment should be discontinued if the platelet count falls below 100,000/mm3.

Arixtra 10 mg / dose (fondaparinux) drug interactions

There are 161 drug interactions with Arixtra 10 mg / dose (fondaparinux)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.